Background
Methods
Participants
Experimental design
Men (n = 11) | Women (n = 9) | |
---|---|---|
Demographic characteristics | ||
Age (yr) | 81.0 ± 1.2 | 81.6 ± 2.7 |
Height (cm) | 174 ± 5.2 | 159 ± 6.7 |
Weight (kg) | 75.8 ± 6.6 | 55.5 ± 6.6 |
Body-mass index (kg/m2) | 25.0 ± 1.6 | 21.8 ± 1.9 |
Lean body mass (kg) | 57.2 ± 4.7 | 37.8 ± 5.2 |
Health status | ||
Physical activity (hrs/week) | 8.5 ± 8.0 | 5.8 ± 5.9 |
≥ 5 times/week ≥30 min exercise (%) | 73 | 56 |
Blood pressure | ||
Systolic (mmHg) | 140 ± 18 | 146 ± 17 |
Diastolic (mmHg) | 81 ± 11 | 82 ± 10 |
Resting heart rate (bpm) | 64 ± 20 | 63 ± 14 |
Gait speed (km/h) | 4.8 ± 0.7 | 4.5 ± 0.7 |
Grip strength (kg) | 41 ± 8.0 | 25 ± 4.5 |
CMV seropositive | 6 (55%) | 7 (78%) |
Use of prescribed medicine | ||
Anti-hypertensive drugs | 2 (18%) | 3 (33%) |
Statins | 2 (18%) | 1 (11%) |
Analgesics | 3 (27%) | 0 (0%) |
Anti-diabetics | 0 (0%) | 0 (0%) |
Othera
| 2 (18%) | 1 (11%) |
Pathology | ||
Hypertension | 2 (18%) | 3 (33%) |
Cardiovascular disease | 2 (18%) | 0 (0%) |
Hypercholestorolemiab
| 2 (18%) | 1 (11%) |
Diabetes | 0 (0%) | 0 (0%) |
Cancer (not further differentiated) | 2 (18%) | 1 (11%) |
Othera
| 1 (9%) | 2 (22%) |
Exercise characteristics | ||
Exercise duration per day (hh:mm) | 7:28 ± 1:10 | 8:07 ± 0:52 |
Speed (km/h) | 4.2 ± 0.1 | 3.7 ± 0.1 |
Average heart rate day 1 (bpm) | 99.5 ± 11.9 | 113.6 ± 14.3 |
Peak heart rate day 1 (bpm) | 112.5 ± 13.1 | 125.0 ± 14.1 |
Exercise intensity day 1 (% of age-adjusted max. heart rate) | 65.7 ± 7.7 | 75.4 ± 9.6 |
Fluid balance | ||
Fluid intake (L)c
| 1.88 ± 0.8 | 1.98 ± 0.8 |
Change in body mass (absolute kg)c
| -0.80 ± 0.9 | -0.19 ± 0.6 |
Change in body mass (relative %)c
| -1.04 ± 1.1 | -0.38 ± 1.0 |
Change in plasma volume (relative %)d
| +3.1 ± 3.2 | +4.5 ± 3.5 |
Subject characteristics
Blood analyses
Detection of CMV-specific IgG
Flowcytometry
Panel | Mab reagent | Clone | Provider |
---|---|---|---|
T cell differentiation | CD3-Efluor 605 | okt-03 | Ebioscience, San Diego, CA, USA |
CD8-APC-H7 | RPA-T8 | Ebioscience, San Diego, CA, USA | |
CD45RO-FITC | UCHL-1 | BD bioscience, San Jose, CA, USA | |
CCR7-PE-Cy7 | 3D12 | BD bioscience, San Jose, CA, USA | |
CD31-AF647 | WM-59 | BD bioscience, San Jose, CA, USA | |
CD28-AF700 | 28.2 | Biolegend, San Diego, CA, USA | |
PD1-PE | EH12.2H7 | Biolegend, San Diego, CA, USA | |
CD4-PcP | SK3 | BD bioscience, San Jose, CA, USA | |
CTLA-4-BV421 | BNI3 | BD bioscience, San Jose, CA, USA | |
Treg/Proliferation | CD8-PE-Cy7 | RPA-T8 | BD bioscience, San Jose, CA, USA |
CD25-APC | BC96 | Ebioscience, San Diego, CA, USA | |
CD45RA-Efluor605 | HI100 | Ebioscience, San Diego, CA, USA | |
CD19-FITC | HD37 | Dako, Santa Clara, CA, USA | |
CD4-APC-H7 | RPA-T4 | BD bioscience, San Jose, CA, USA | |
FOXP3-PE | PCH101 | BD bioscience, San Jose, CA, USA | |
Ki-67-PcP-Cy5.5 | B56 | BD bioscience, San Jose, CA, USA | |
NK cell | CD16-FITC | 3G8 | Beckman Coulter, Brea, CA, USA |
Inhibitory receptors | CD56-ECD | N901 | Beckman Coulter, Brea, CA, USA |
CD3-APC-AF750 | UCHT1 | Beckman Coulter, Brea, CA, USA | |
CD45-KO | J.33 | Beckman Coulter, Brea, CA, USA | |
CD159c (NKG2C)-PE | 134591 | R&D Systems, Minneapolis, MN, USA | |
CD158b (KIR2DL2/3)-PE-Cy7 | GL183 | Beckman Coulter, Brea, CA, USA | |
CD158e1 (KIR3DL1)-APC | Z27.3.7 | Beckman Coulter, Brea, CA, USA | |
CD158a (KIR2DL1)-APC-AF700 | EB6B | Beckman Coulter, Brea, CA, USA | |
CD159a (NKG2A)-PB | Z199 | Beckman Coulter, Brea, CA, USA | |
NK cell | CD16-FITC | 3G8 | Beckman Coulter, Brea, CA, USA |
Activating receptors | CD56-ECD | N901 | Beckman Coulter, Brea, CA, USA |
CD3-APC-AF750 | UCHT1 | Beckman Coulter, Brea, CA, USA | |
CD45-KO | J.33 | Beckman Coulter, Brea, CA, USA | |
CD336 (NKp44)-PE | Z231 | Beckman Coulter, Brea, CA, USA | |
CD337 (NKp30)-PE-Cy5.5 | Z25 | Beckman Coulter, Brea, CA, USA | |
CD335 (NKp46)-PE-Cy7 | BAB281 | Beckman Coulter, Brea, CA, USA | |
CD314 (NKG2D)-APC | ON72 | Beckman Coulter, Brea, CA, USA | |
CD244 (2B4) -APC-AF700 | C1.7.1 | Beckman Coulter, Brea, CA, USA | |
CD161-PB | 191B8 | Beckman Coulter, Brea, CA, USA |
Lipopolysacharide (LPS)-stimulated PBMC cytokine production
Statistical analyses
Results
Subject characteristics
Effects of acute exercise on the peripheral blood cellular composition
Pre-Walking | Post-Walking |
P-value | |
---|---|---|---|
Hemoglobin (mmol/L) | 8.7 (7.7–9.4) | 8.2 (7.3–9.1) | 0.0009 |
Thrombocytes (109/L) | 233 (157–318) | 234 (160–349) | ns |
CRP (mg/L) | 1 (1–9) | 1 (1–47) | 0.0078 |
Creatinin (μmol/L) | 86 (47–147) | 100 (54–207) | 0.0008 |
ASAT (U/L) | 28 (14–39) | (-) | (-) |
ALAT (U/L) | 28 (21–46) | (-) | (-) |
Leukocytes (109/L) | 6.6 (4.6–11.0) | 7.7 (5.7–14.3) | 0.0002 |
Neutrophils (109/L) | 4.1 (2.4–8.3) | 5.1 (2.9–10.4) | 0.0008 |
Eosinophils (109/L) | 0.15 (0.03–0.68) | 0.18 (0.06–0.78) | 0.0166 |
Basophils (109/L) | 0.04 (0.01–0.07) | 0.03 (0.02–0.05) | ns |
Monocytes (109/L) | 0.49 (0.29–0.90) | 0.67 (0.40–1.21) | 0.0005 |
Lymphocytes (109/L) | 1.57 (1.00–2.21) | 1.82 (1.07–2.97) | 0.0045 |
CD3+ T cells (109/L) | 0.75 (0.20–1.36) | 1.11 (0.48–1.98) | 0.0005 |
CD4+ T cells (109/L) | 0.46 (0.06–0.99) | 0.59 (0.37–1.62) | 0.0007 |
CD8+ T cells (109/L) | 0.15 (0.03–0.45) | 0.15 (0.05–0.71) | 0.0061 |
CD19+ B cells (109/L) | 0.23 (0.05–0.40) | 0.30 (0.09–0.51) | 0.0023 |
CD16 + CD56+ NK cells (109/L) | 0.40 (0.21–0.87) | 0.31 (0.13–0.70) | 0.0178 |
CMV+ | CMV- | |||
---|---|---|---|---|
Before | After | Before | After | |
Hemoglobina (mmol/L) | 8.4 (7.7–9.4) | 7.9 (7.3–8.7)** | 8.9 (7.9–9.0) | 8.7 (7.5–9.1) |
CRP (mg/L) | 1 (1–9) | 1 (1–10) | 1 (1–6) | 9 (1–47) |
Leukocytes (109/L) | 6.6 (4.6–11.0) | 7.9 (5.7–14.3)** | 6.6 (4.8–9.1) | 7.2 (6.3–12.3)* |
Neutrophils (109/L) | 3.8 (2.4–8.3) | 5.0 (2.9–10.4)* | 4.2 (3.2–6.6) | 5.1 (4.2–9.2)* |
Eosinophils (109/L) | 0.12 (0.03–0.68) | 0.19 (0.06–0.78)** | 0.17 (0.08–0.28) | 0.15 (0.08–0.33) |
Basophils (109/L) | 0.03 (0.01–0.06) | 0.03 (0.02–0.05) | 0.05 (0.02–0.07) | 0.04 (0.03–0.05) |
Monocytes (109/L) | 0.48 (0.29–0.69) | 0.68 (0.40–1.05)** | 0.57 (0.32–0.90) | 0.66 (0.42–1.21) |
Lymphocytes (109/L) | 1.65 (1.45–2.21) | 2.19 (1.33–2.97)** | 1.37 (1.00–1.92) | 1.40 (1.07–2.08) |
CD3+ T cells (109/L) | 0.77 (0.49–1.36) | 1.19 (0.73–1.98)** | 0.63 (0.20–1.00) | 0.76 (0.48–1.45) |
CD4+ T cells (109/L) | 0.52 (0.17–0.99) | 0.73 (0.40–1.62)** | 0.40 (–0.06–0.69) | 0.57 (0.37–0.87) |
CD8+ T cells (109/L) | 0.21 (0.04–0.45) | 0.21 (0.06–0.72)* | 0.08 (0.04–0.17) | 0.10 (0.05–0.19) |
CD19+ B cells (109/L) | 0.26 (0.09–0.40) | 0.35 (0.11–0.51)* | 0.10 (0.05–0.40) | 0.16 (0.09–0.45)* |
CD16 + CD56+ NK cells (109/L) | 0.32 (0.21–0.87) | 0.31 (0.13–0.70) | 0.43 (0.38–0.52) | 0.29 (0.22–0.43)* |